期刊： HELICOBACTER, 2022; 27 (1)
Background Information on the management of Helicobacter (H.) pylori infection by gastroenterologists and gastroenterology fellows are scarce. We aime......
期刊： HELICOBACTER, 2022; 27 (1)
Background Multiple studies have reported the association between Helicobacter pylori (H. pylori) infection and children's growth. The results of thes......
期刊： HELICOBACTER, 2022; 27 (3)
For decades, traditional in vitro and in vivo models used for the study of Helicobacter pylori infection have relied heavily on the use of gastric can......
期刊： HELICOBACTER, 2022; 27 (5)
Background Resistance of Helicobacter pylori (H. pylori) to antibiotics is an evolving and dynamic process. Presence of antibiotic resistance impacts ......
期刊： HELICOBACTER, 2022; 27 (5)
Background The oral cavity is considered a potential reservoir of Helicobacter pylori (H. pylori), and the imbalance of oral microbiota directly refle......
期刊： HELICOBACTER, 2022; 27 (6)
Background and Aim Helicobacter pylori eradication has been shown to reduce the risk of gastric cancer (GC), with the number of eradication therapy ca......
期刊： HELICOBACTER, 2022; 27 (4)
Background About a half of the world's population is infected with Helicobacter pylori (H. pylori), but only 1%-3% of them develop gastric cancer. As ......
期刊： HELICOBACTER, 2022; 27 (4)
Background: Helicobacter pylori (H. pylori) infection and its related diseases are substantial public health burden for highly infected areas. Recentl......
期刊： HELICOBACTER, 2022; 27 (5)
Background: The currently recommended quadruple regimens as rescue therapy on Helicobacter pylori infection were not as effective as being supposed, e......
期刊： HELICOBACTER, 2022; 27 (6)
Background One main challenge in Helicobacter pylori (H. pylori) eradication is its increasing antibiotic resistance. Additionally, resistance rates v......
期刊： HELICOBACTER, 2022; 27 (2)
Background and aims: As with other infectious diseases, Helicobacter pylori eradication regimens should be guided by susceptibility testing to achieve......
期刊： HELICOBACTER, 2022; 27 (3)
Background Helicobacter pylori infection is the leading cause of peptic ulcer and chronic gastritis and may initiate gastric carcinogenesis following ......
期刊： HELICOBACTER, 2022; 27 (4)
Background Rifabutin-based regimens are used as rescue therapy for refractory Helicobacter pylori infection; however, the duration for which treatment......
期刊： HELICOBACTER, 2022; 27 (2)
Background and objective: The tumor microenvironment and tumor immunity are crucially involved in tumor therapy. Immune checkpoint inhibitors targetin......
